Q3 2020 Sales Performance
Q3 performance
Pharma and Consumer growth drivers and cost control offset pandemic impacts
Pharmaceuticals
-3% CER
Vaccines
-9% CER
Consumer
Healthcare
+2% CER
New & Specialty Pharma +12%*
Respiratory products +26%**
HIV flat; 2DRs £222m, +94%
Benlysta +13%; Oncology £99m, +58%
Shingrix £374m, -25%
Meningitis +1%
Influenza +21%
Pro forma -6%, (+3% excluding brands divested
or under review)
Gaining share overall and with power brands;
VMS +18%, Oral Health +5%
All growth rates and margin changes at CER. VMS: vitamins, minerals and supplements
gsk
Group sales -3%,
pro forma -5%
30.8% Adjusted
operating margin;
+2.4 pp pro forma
Total EPS
25.0p, -9%;
Adjusted EPS
35.6p, +1%
FCF £2.3 billion YTD
The definitions for non-IFRS measures are set out on pages 10, 11 and 62 of our Third Quarter 2020 earnings release, and reconciliations are set out on pages 23 and 62.
* New & Specialty Pharma comprises Pharmaceuticals excluding Established Pharmaceuticals Respiratory comprises the Ellipta portfolio and Nucala
**
86
98View entire presentation